Prescription Required
Ipca MMF 500mg Tablet is an immunosuppressive medication primarily used to prevent organ rejection in patients who have undergone kidney, heart, or liver transplants. By suppressing the immune system, it reduces the likelihood of the body attacking the transplanted organ. Each tablet contains 500mg of Mycophenolate Mofetil, a potent agent that inhibits immune responses.
Organ transplantation is a critical procedure, and preventing rejection is essential for the success of the transplant. Ipca MMF 500mg Tablet plays a vital role in ensuring the longevity and functionality of the transplanted organ by modulating the body's immune response. This medication is often used in combination with other immunosuppressants to enhance its efficacy.
Limited information is available regarding the use of Ipca MMF 500mg Tablet in patients with liver disease. Consult your doctor for personalized advice.
Patients with severe kidney disease should use this medication with caution. Dose adjustments may be necessary. Regular monitoring of kidney function is recommended.
Alcohol consumption with Ipca MMF 500mg Tablet does not show any harmful interaction.
Ipca MMF 500mg Tablet may cause dizziness or drowsiness. If affected, avoid driving or operating heavy machinery.
Ipca MMF 500mg Tablet can cause birth defects and miscarriages. Women of childbearing age should use effective contraception during treatment and for six weeks after discontinuation. Consult your doctor if you are pregnant or planning to become pregnant.
Mycophenolate Mofetil can pass into breast milk and may harm the nursing infant. Breastfeeding is not recommended during treatment.
Ipca MMF 500mg Tablet contains Mycophenolate Mofetil, which is converted in the body to mycophenolic acid. This active metabolite inhibits an enzyme called inosine monophosphate dehydrogenase (IMPDH), crucial for the proliferation of T and B lymphocytes—white blood cells responsible for immune responses. By suppressing the activity of these cells, the medication reduces the risk of the immune system attacking the transplanted organ, thereby preventing rejection.
If you miss a dose:
Organ rejection in transplant patients occurs when the immune system recognizes the transplanted organ as a foreign object and attacks it. This can lead to severe complications, including loss of the transplanted organ.
Ipca MMF 500mg Tablet is a trusted immunosuppressant designed to prevent organ rejection in transplant patients. With Mycophenolate Mofetil (500mg) as its active ingredient, it works by suppressing immune cell activity, ensuring that the body accepts the transplanted organ. Regular monitoring, adherence to dosage, and a healthy lifestyle can maximize its effectiveness and ensure long-term transplant success. Always consult your healthcare provider before making any changes to your treatment.
Content Updated on
Monday, 10 Feburary, 2025Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA